The West of Scotland coronary prevention study: Economic benefit analysis of primary prevention with pravastatin

BMJ

Volumn 315, Issue 7122, 1997, Pages 1577-1582

  Caro, J ^a   Klittich, W ^a   Mcguire, A ^b   Ford, I ^c   Norrie, J ^c   Pettitt, D ^d   Mcmurray, J ^c   Shepherd, J ^e  

^a CARO RESEARCH INSTITUTE   (United States)

^b CITY UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d BRISTOL MYERS SQUIBB   (United States)

^e GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PRAVASTATIN;

ARTICLE; CARDIOVASCULAR DISEASE; COST BENEFIT ANALYSIS; HEALTH CARE COST; HEALTH ECONOMICS; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; PRIMARY PREVENTION; PRIORITY JOURNAL; UNITED KINGDOM;

ANTICHOLESTEREMIC AGENTS; CORONARY DISEASE; COST-BENEFIT ANALYSIS; DRUG COSTS; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PRAVASTATIN; SCOTLAND; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 0030815287     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.315.7122.1577     Document Type: Article

References (15)

1. On the State of the Public Health. The annual report of the chief medical officer of the Department of Health for the year 1994. London: HMSO, 1995.
2. Health in Scotland. Report of the chief medical officer on the state of Scotland's health for the year 1994. Edinburgh: HMSO, 1995.
3. Secretary of State for Health. The health of the nation: a strategy for health in England. London: HMSO, 1992.
4. The West of Scotland Coronary Prevention Study Group. A coronary primary prevention study of Scottish men aged 45–64 years: trial design. J Clin Epidemiol 1992; 45: 849–860.
5. Shepherd J, Cobbe SM, Ford I, Isles C, Lorimer AR, Macfarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301–1307.
6. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995; 310: 452–454.
7. Registrar General Scotland. Annual report 1994. Edinburgh: HMSO, 1995.
8. Kendrick S, Clarke J. The Scottish record linkage system. Health Bull (Edin) 1993; 51: 72–79.
9. Tsevat J, Goldman L, Soukup JR, Lamas GA, Connors KF, Chapin CC, et al. Stability of time-tradeoff utilities in survivors of myocardial infarction. Med Decis Making 1993; 13: 161–165.
10. Rose G, McCartney P, Reid DD. Self administration of a questionnaire on chest pain: intermittent claudication. Br J Prev Soc Med 1977; 31: 42–48.
11. Pyörälä K, De Backer G, Graham I, Poole-Wilson P, Wood D. Prevention of coronary heart disease in clinical practice. Recommendations of the task force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994; 15: 1300–1331.
12. O'Brien JA, Caro JJ, Klittich WS. Beyond acute care: the true cost of stroke. Clin Therapeut 1996; 149: 21.
13. Pharoah PDP, Hollingworth W. Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population. BMJ 1996; 312: 1443–1448.
14. Stinnet AA, Mittleman MA, Weinstein MC, Kuntz KM, Cohen DJ, Williams LW, et al. Appendix C: the cost-effectiveness of dietary and pharmacologic therapy for cholesterol reduction in adults. In: Gold MR,Siegel JE,Russell LB,Weinstein MC, eds. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996: 349–391.
15. Jönsson B, Johannesson M, Kjekshus J, Olsson AG, Pedersen TR, Wedel H. Cost-effectiveness of cholesterol lowering. Results from the Scandinavian simvastatin survival study (4S). Eur Heart J 1996; 17: 1001–1007.